Drug Database
Back to search

Netherlands· NL-2450f27b54df

AUGTYRO 160 mg harde capsules

A repotrectinib product containing repotrectinib, registered in Netherlands by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 10 of our 19 countries.

ATC L01EX28

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedAUGTYRO 160 mg harde capsulesATCL01EX28REGISTER NO.NL-2450f27b54dfPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about repotrectinibAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Repotrectinib is registered in 10 of 19 countries.

Countries holding a registration under ATC L01EX28 (repotrectinib), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose
Search repotrectinib products by name

Repotrectinib · ATC L01EX28

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
REPOTRECTINIB
Manufacturer
Bristol-Myers Squibb Pharma EEIG
Country
Netherlands (NL)
ATC code
L01EX28
ATC class
Repotrectinib
Defined daily dose
0.32 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/24/1883

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Repotrectinib in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All repotrectinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Augtyro
  • Liechtenstein · Augtyro
  • Norway · Augtyro

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/62d6f7fc-067b-4322-b910-f023116efb23
GET /v1/drugs/62d6f7fc-067b-4322-b910-f023116efb23?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/augtyro-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Repotrectinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp132614",
  "excipients": [
    "BRILJANTBLAUW FCF (E 133)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "GELATINE (E 441)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMLAURILSULFAAT",
    "SCHELLAK (E 904)",
    "SILICIUMDIOXIDE (E 551)",
    "TITAANDIOXIDE (E 171)",
    "TITAANDIOXIDE (E 171)",
    "WITTE INKT"
  ],
  "substances": [
    "REPOTRECTINIB"
  ],
  "leaflet_url": null,
  "authorised_at": "2025/01/13",
  "procedure_number": "EMEA/H/C/006005",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/24/1883",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about repotrectinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console